| Trial ID: | L3843 |
| Source ID: | NCT01356381
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Vildagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Measure: effect of treatment on insulin sensitivity, assessed as glucose Rd (rate of glucose disposal)., 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
43
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2011-04
|
| Completion Date: |
2013-08
|
| Results First Posted: |
|
| Last Update Posted: |
2013-08-30
|
| Locations: |
Novartis Investigative Site, Newcastle Upon Tyne, NE4 5PL, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01356381
|
